An observational study in Breast Cancer, sponsored by University of Washington. Active, not recruiting at 2 sites in United States. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by University of Washington · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Breast Neoplasms by University of Washington — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · University of Washington.
Among the 64 studies in Breast Neoplasms by University of Washington, this one is one of 3 that started in 2018, is one of 7 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 49th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →7 of the 64 studies in Breast Neoplasms by University of Washington are open now, in 1 country. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 80 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 1
First in 1996; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 269 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 35 across the 56 interventional studies, 100 across the 7 observational. Of the 50 that completed or were terminated, 23 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
5 of the studies in Breast Neoplasms by University of Washington that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04329065University of WashingtonConcurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer | 2026-12-31 |
| NCT07858825University of WashingtonDesign and Pilot Implementation of a Chatbot to Support Breast Cancer Screening Among Black Women | 2027-03-01 |
| NCT06179303University of WashingtonFunctional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | 2027-03-01 |
| NCT03607552University of WashingtonNon-contrast DWI for Supplemental Screening | 2027-07 |
| NCT06518057University of WashingtonHippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer | 2027-07-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 64 studies in Breast Neoplasms by University of Washington, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diffusion-weighted imaging (DWI) is a short (under 5 minutes) non-contrast MRI technique that has shown promise for the detection and characterization of breast cancer. Our preliminary data has shown that DWI holds potential for detecting mammographically and clinically-occult breast cancers. However, current technical limitations reduce the sensitivity of DWI for screening applications.
The identification of a screening tool to complement mammography that is more accurate than ultrasound and faster, less expensive, and safer than conventional contrast-enhanced MRI would have significant clinical impact by improving the early detection of cancer in women with dense breasts. We hypothesize that an optimized DWI approach will enable detection of mammographically occult breast cancer in women with dense breasts with high sensitivity and low false positive rate.
Hypothesis: With technical optimizations, non-contrast DWI can detect clinically and mammographically occult breast cancer in women with dense breasts with high sensitivity and low false positive rate.
Aim 1: Improve the breast DWI technique to maximize spatial resolution, reduce distortion, and increase lesion contrast.
Aim 2: Develop interpretation tools to optimize diagnostic performance for detecting cancer on DWI.
Aim 3: Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
Women age 18+, with mammographically identified dense breasts, referred for clinical breast MRI
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Optimize DWI sequences to maximize spatial resolution, reduce distortion, and increase lesion contrast.
Device: Non-contrast DWI
Develop interpretation tools to optimize diagnostic performance for detecting cx on DWI.
Device: Non-contrast MRI
Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
Device: Non-contrast MRI
Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium.
Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.
Diffusion sensitization (b value)
Identify optimal b value to maximize conspicuity of cancers in women with dense breasts
Time frame: 2.5 years
Reader Interpretation strategy
Identify optimal ADC thresholds to differentiate malignant from benign lesions
Time frame: 3.5 years
Specificity
Specificity will be assessed for non-contrast DWI
Time frame: 4.5 years
Sensitivity
Sensitivity will be assessed for non-contrast DWI
Time frame: 4.5 years
Plan to share: No
Started Jul 2018 (actual). Primary completion is estimated for Jul 2027, 108 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 108 months is above that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jul 2027, on Nov 10, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.